Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Case Series
| Autor: | Alfred Zippelius, Günther F.L. Hofbauer, Natalie Fischer, Bahar Shafaeddin-Schreve, R. Wintherhalder, Katrin Conen, Christoph Rochlitz |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cisplatin
Response rate (survey) medicine.medical_specialty Cetuximab biology business.industry Hematology medicine.disease Gastroenterology Rash Sepsis Stable Disease Oncology Internal medicine biology.protein Medicine Epidermal growth factor receptor medicine.symptom business Progressive disease medicine.drug |
| Zdroj: | Annals of Oncology. 23:ix372-ix373 |
| ISSN: | 0923-7534 |
| Popis: | Background Treatment of metastatic squamous cell cancer of the skin (SCCS) is challenging. Only few therapeutic options including cisplatin-based combinations are currently available. In a recently published phase II trial, cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGRF), has demonstrated a promising clinical activity with an overall 69% disease control rate (DCR) and 28% response rate (RR) in patients with unresectable SCCS. Whether this treatment is also effective in metastatic SCCS is unclear. Purpose To summarize the efficacy of cetuximab at any line in a series of patients with metastatic SCCS. Patients and methods We performed a retrospective analysis of six patients from four centres in Switzerland. We collected standard baseline data by reviewing the patients' records. Endpoints were DCR at 4-8 weeks, 12-14 weeks and 20-36 weeks of treatment. In addition, we evaluated the treatment-related toxicity. Results The median age of the patients was 67 years. A total of 10 cycles in median were applied (range 1-21). The DCR was 67% (4 of 6 patients) at 4-8 weeks, 50% (3 of 6 patients) at 12-14 weeks, and 33% (2 of 6 patients) at 20-26 weeks (Table 1). One patient showed a complete response (CR) after 4 weeks of treatment and is still in remission since then. Death due to sepsis occurred in one patient. 83% (5 of 6 patients) developed Grade I-III acne-like rash around week 3 of treatment. All patients who had their disease controlled at 4-8 weeks showed an acne-like rash (4 of 6 patients), 1 patient had a rash without disease control. Conclusions Cetuximab treatment in patients with metastatic SCCS achieved an overall DCR of 57% at 4-8 weeks of treatment. 1 of 6 patients had a CR. These data suggest that cetuximab may be effective in this setting. Response and disease control rates. Response at 4-8 weeks 12-14 weeks 20-36 weeks Variable No % No % No % Complete response 1 17 1 17 1 17 Partial response 3 50 1 17 1 17 Stable disease 0 0 1 17 0 0 Progressive disease 2 33 1 17 1 17 Disease control rate 67 50 33 Disclosure All authors have declared no conflicts of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|